The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy

被引:0
|
作者
Lu Chen
Jingjuan Huang
Weihua Wu
Shengjun Ta
Xiaoyi Xie
机构
[1] Shanghai Chest Hospital,Department of Ultrasound
[2] Shanghai Jiao Tong University,Department of Cardiology
[3] Shanghai Chest Hospital,Department of Ultrasound
[4] Shanghai Jiao Tong University,undefined
[5] Yan’an People’s Hospital,undefined
来源
The International Journal of Cardiovascular Imaging | 2019年 / 35卷
关键词
Right ventricle; Strain; Chemoradiotherapy; Non-small cell lung cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Right ventricular (RV) impairment after cancer therapy-related cardiotoxicity and its prognostic implications in lung cancer have not been examined. The present research sought to evaluate RV structure, function, and mechanics in stage III non-small-cell lung cancer (NSCLC) before and after concurrent chemoradiotherapy (CCRT), and to explore the associations between RV impairments, radiation dose, and all-cause mortality. This prospective investigation included 128 inoperable NSCLC patients who were scheduled to receive CCRT. Echocardiographic examination and strain evaluation was performed at baseline and 6 months post-CCRT in all participants. Conventional RV dimensions revealed no significant changes post-CCRT. However, a reduction in RV free wall strain (RV-fwLS) was observed at 6 months post-CCRT (− 28.3 ± 4.6% vs. − 25.5 ± 4.8%, P < 0.001). The same was revealed for global RV longitudinal strain (RV-GLS) (− 23.4 ± 2.9% vs. − 20.2 ± 3.4%, P < 0.001). Pearson correlation showed that RV radiation mean dose was related with the percentage change in RV-fwLS (r = 0.303, P = 0.001) and RV-GLS (r = 0.284, P = 0.002). In multivariable analysis, the percentage change in RV-fwLS was an independent predictor of all-cause mortality (HR 1.296, 95% CI 1.202–1.428, P < 0.001). RV longitudinal strain is deteriorated at 6 months post-CCRT. The RV mechanics deterioration was associated with radiation dose and affected the long-term outcome of stage III NSCLC patients treated with CCRT.
引用
收藏
页码:1009 / 1017
页数:8
相关论文
共 50 条
  • [41] Nivolumab Plus Ipilimumab in Relapsed Stage III Non-Small Cell Lung Cancer After Durvalumab Following Chemoradiotherapy
    Tokito, T.
    Mouri, A.
    Watanabe, S.
    Nagai, Y.
    Imai, H.
    Yamaguchi, O.
    Saida, Y.
    Kobayashi, K.
    Kaira, K.
    Kagamu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S589 - S589
  • [42] Stage III Non-Small Cell Lung Cancer Clinical Outcomes with Surgical Resection After Definitive Neoadjuvant Chemoradiotherapy
    Caturegli, I.
    Vyfhuis, M.
    Burrows, W.
    Suntharalingam, M.
    Badiyan, S.
    Scilla, K.
    Carr, S.
    Friedberg, J.
    Henry, G.
    Stewart, S.
    Ii, C. Simone
    Mohindral, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S462 - S463
  • [43] Myelosuppression induced by concurrent chemoradiotherapy as a prognostic factor for patients with locally advanced non-small cell lung cancer
    Kishida, Yukiko
    Hirose, Takashi
    Shirai, Takao
    Sugiyama, Tomohide
    Kusumoto, Soujiro
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Adachi, Mitsuru
    Nakamura, Akihiro
    ONCOLOGY LETTERS, 2011, 2 (05) : 949 - 955
  • [44] Concurrent chemoradiotherapy with weekly carboplatin and paclitaxel may be a feasible option in inoperable stage III non-small cell lung cancer: a single center experience
    Calikusu, Zuleyha
    Sedef, Ali Murat
    Saltaoglu, Pinar
    CUKUROVA MEDICAL JOURNAL, 2019, 44 (01): : 195 - 199
  • [45] The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy
    Koo, Tae Ryool
    Moon, Sung Ho
    Lim, Yu Jin
    Kim, Ja Young
    Kim, Yeonjoo
    Kim, Tae Hyun
    Cho, Kwan Ho
    Han, Ji-Youn
    Lee, Young Joo
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    RADIATION ONCOLOGY, 2014, 9
  • [46] TIME TO TREATMENT IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER
    Wang, Li
    Correa, Candace R.
    Hayman, James A.
    Zhao, Lujun
    Cease, Kemp
    Brenner, Dean
    Arenberg, Doug
    Curtis, Jeffery
    Kalemkerian, Gregory P.
    Kong, Feng-Ming
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (03): : 790 - 795
  • [47] Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer
    Topkan, Erkan
    Selek, Ugur
    Ozdemir, Yurday
    Yildirim, Berna A.
    Guler, Ozan C.
    Mertsoylu, Huseyin
    Hahn, Stephen M.
    LUNG CANCER, 2018, 121 : 30 - 36
  • [48] Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer
    Kozono, David E.
    Stinchcombe, Thomas E.
    Salama, Joseph K.
    Bogart, Jeffrey
    Petty, W. Jeffrey
    Guarino, Michael J.
    Bazhenova, Lyudmila
    Larner, James M.
    Weiss, Jared
    DiPetrillo, Thomas A.
    Feigenberg, Steven J.
    Chen, Xin
    Sun, Zhaowen
    Nuthalapati, Silpa
    Rosenwinkel, Lindsey
    Johnson, Eric F.
    Bach, Bruce A.
    Luo, Yan
    Vokes, Everett E.
    LUNG CANCER, 2021, 159 : 56 - 65
  • [49] Chemoradiotherapy versus Radiotherapy Alone in Elderly Patients with Stage III Non-Small Cell Lung Cancer: A Systematic Review
    Dawe, David E.
    Christiansen, David
    Zarychanski, Ryan
    Abou-Setta, Ahmed
    Ellis, Peter M.
    Swaminath, Anand
    Rothney, Janet
    Rabbani, Rasheda
    Mahmud, Salah
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S286 - S286
  • [50] Management of stage III non-small cell lung cancer
    Tabchi, Samer
    Kassouf, Elie
    El Rassy, Elie
    Kourie, Hampig Raphael
    Martin, Jocelyne
    Campeau, Marie-Pierre
    Tehfe, Mustapha
    Blais, Normand
    SEMINARS IN ONCOLOGY, 2017, 44 (03) : 163 - 177